LiveWire Ergogenics (LVVV) AI Stock Analysis

• Market Cap: $1.14M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 176.72
• Revenue Growth: -81.39%
• EPS Growth: -100.00%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 1,903,979,100
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.00
• Price to Book (P/B): -0.87
• Price to Sales (P/S): 168.12
• P/FCF Ratio: -180.19
• Enterprise Value/Market Cap: 3.89
• Enterprise Value/Revenue: 567.16
• Enterprise Value/Gross Profit: -925.19
• Enterprise Value/Ebitda: -54.08
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.01 ▲(1150.00% Upside)
• Action: Reiterated Date: 03/22/26
• Date: Action: Reiterated 03/22/26

The score is driven primarily by weak financial performance, highlighted by a severe 2025 revenue collapse, large net loss, and negative shareholders’ equity. Valuation is also challenged by a negative P/E with no dividend yield provided, while technical analysis is neutral due to missing indicators.

Positive Factors

Cannabis-focused holding model

The holding-company model centered on acquiring, developing and operating cannabis cultivation properties provides asset-backed optionality. Owning and operating properties can create diversified revenue levers (leases, operations, JV arrangements) and preserves strategic flexibility over months.

Historic cash generation capability

The company produced positive operating and free cash flow in prior years, including ~$125K in 2024, demonstrating an ability to generate liquidity under prior operating conditions. This historical cash generation provides a baseline capability that can support short-term operations or restructuring actions.

Extremely lean operating footprint

A reported headcount of one indicates a very low fixed labor cost base and a lean operating structure. Low payroll overhead can help conserve cash, enable rapid cost adjustments, and make the company more nimble when redeploying capital or pursuing partnerships over the medium term.

Negative Factors

Severe revenue collapse and volatility

A dramatic fall in sales to roughly $7.8K in 2025 from prior years shows extreme demand or execution deterioration. Such severe revenue volatility undermines predictable cash generation, complicates planning, and materially raises the risk that operations cannot sustainably cover costs or service obligations in the near term.

Negative shareholders' equity

Negative shareholders’ equity reflects accumulated losses and asset contraction, removing the usual capital cushion. This condition reduces financing flexibility, may limit access to new capital on reasonable terms, and signals weakened financial resilience that materially constrains strategic options.

Meaningful debt with eroded cash flow

About $3.05M of debt combined with operating cash flow turning slightly negative (~-$7K) increases refinancing and liquidity risk. Meaningful leverage when cash generation has reversed limits runway, elevates default or covenant risk, and constrains the company's ability to invest or recover over the medium term.

LiveWire Ergogenics Business Overview & Revenue Model

Company Description

LiveWire Ergogenics Inc. focuses on acquiring, managing, and licensing special purpose real estate properties to produce handcrafted and organically grown cannabis products for medical and recreational adult-use in California. The company is based in Anaheim, California.

How the Company Makes Money

null

LiveWire Ergogenics Financial Statement Overview

Summary

Income statement and balance sheet signals are highly adverse: 2025 revenue collapsed to ~$7.8K with gross profit turning negative and a large net loss (~-$4.78M). The balance sheet weakened materially with shareholders’ equity turning negative (~-$1.51M) alongside asset contraction, while debt remains meaningful (~$3.05M). Cash flow also flipped slightly negative in 2025 after prior years’ positives, reinforcing volatility and elevated financial risk.

Income Statement

Results deteriorated sharply in the latest annual period (2025) with revenue collapsing to ~$7.8K (vs. ~$304K in 2024 and ~$1.63M in 2023), turning gross profit negative and driving a very large net loss (~-$4.78M). While 2022–2024 showed periods of reported profitability and strong margins, the recent step-change down in sales and earnings suggests a highly unstable operating profile and elevated execution risk.

Balance Sheet

Leverage remains meaningful (total debt ~$3.05M in 2025), and the balance sheet weakened materially as shareholders’ equity turned negative in 2025 (~-$1.51M), reducing financial flexibility. Total assets also declined significantly (~$2.26M in 2025 vs. ~$7.96M in 2024), indicating balance-sheet contraction. Prior years showed positive equity, but the latest year’s negative equity is a major red flag.

Cash Flow

Cash generation is inconsistent: operating cash flow and free cash flow were positive in 2022–2024 (including ~$125K in 2024), but both turned slightly negative in 2025 (about -$7K), aligning with the sharp earnings and revenue deterioration. The company has demonstrated an ability to produce cash in some years, but the latest reversal and volatility lower confidence in cash-flow durability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.83K	7.83K	304.12K	1.63M	1.94M	851.20K
Gross Profit	-4.80K	-17.44K	285.16K	1.59M	1.80M	701.55K
EBITDA	-82.17K	-157.16K	322.18K	1.22M	1.07M	-2.68M
Net Income	-1.17M	-4.78M	78.72K	921.58K	684.12K	-3.43M
Balance Sheet
Total Assets	2.63M	2.26M	7.96M	7.74M	6.27M	4.52M
Cash, Cash Equivalents and Short-Term Investments	1.67K	1.48K	11.27K	27.87K	76.38K	199.95K
Total Debt	3.53M	3.05M	3.35M	3.34M	3.20M	2.85M
Total Liabilities	4.16M	3.78M	4.70M	4.62M	4.24M	3.61M
Stockholders Equity	-1.54M	-1.51M	3.24M	3.11M	2.03M	912.13K
Cash Flow
Free Cash Flow	11.44K	-7.31K	124.74K	682.37K	396.37K	-467.21K
Operating Cash Flow	11.43K	-7.31K	124.74K	682.37K	396.37K	-399.89K
Investing Cash Flow	0.00	0.00	-187.34K	-857.40K	-1.20M	-930.51K
Financing Cash Flow	0.00	0.00	46.00K	126.51K	684.50K	1.42M

LiveWire Ergogenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$4.14M	-0.76	-203.36%	―	―	90.53%
PRFX	44 Neutral	$1.79M	-0.13	―	―	―	―
LVVV	41 Neutral	$1.14M	-0.66	―	―	-81.39%	-100.00%
MSPR	40 Underperform	$475.14K	-2.13	―	―	-8.57%	-52.17%